Podcasts about cancer care

Researchers at Toronto's Princess Margaret Cancer Centre have launched a major study to see if a simple blood test can detect microscopic traces of cancer left behind after treatment. If successful, it could allow doctors to identify a cancer recurrence long before it appears on a scan. To talk about this potential breakthrough, Tamara is joined by Dr. Lillian Siu, medical oncologist at Princess Margaret Cancer Centre, Professor of Medicine at the University of Toronto, and Scientific Lead of the Peter Gilgan Centre for Early Cancer Detection Research.

What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda's 16‑year survivorship story and Dr. Smoot's lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors. How to listen and stay connected: Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode. Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: https://mayocl.in/3EcNPNc Connect with Mayo Clinic: Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/ Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic

July 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, speaks with host Rakesh Dixit, Ph.D. about what “next-generation ADCs” should mean if we care about patients, not just pipeline counts. Their conversation gets specific about where differentiation comes from: novel payloads with new mechanisms of action, better therapeutic index choices, and smarter design decisions that reduce the toxicities that make patients quit therapy early. They also pressure-test the hype around bispecific ADCs and dual-payload ADCs.  Links from this episode:  Adcytherix 

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Although many GISTs can be effectively treated with targeted therapies, their response to treatment depends largely on the specific genetic alterations driving tumor growth. Advances in molecular testing have transformed the management of these tumors, allowing clinicians to tailor treatment based on each patient's genetic profile. A case report published in Volume 17 of Oncotarget, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report,” describes an exceptionally rare case involving a patient whose tumor carried two genetic alterations that are traditionally considered mutually exclusive. Full blog post - https://www.oncotarget.org/2026/07/13/rare-genetic-combination-in-gastrointestinal-tumor-offers-new-insights-into-precision-cancer-care/ DOI - https://doi.org/10.18632/oncotarget.28863 Correspondence to - Joseph G. Crompton - jcrompton@mednet.ucla.edu Abstract video - https://www.youtube.com/watch?v=eB_QG2vBNCE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28863 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, GIST, KIT duplication, SDHC mutation, genetic testing, case report To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

In this episode, Dr. Robert Figlin, Cedars-Sinai Cancer Institute, discusses improving patient access to specialized cancer care, expanding clinical trial opportunities, and using AI to streamline care delivery. He also shares why advances in research and innovation are giving oncology leaders more reason for optimism than ever before.

In this episode, Richard Barakat, MD, Physician-in-chief & Executive Director at Northwell Health Cancer Institute, discusses expanding access to advanced cancer therapies, integrating AI into oncology care, and driving the future of precision medicine. He also shares insights on improving efficiency, survivorship care, and clinical trial access for all patients.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

In this week's Talking Life, Rory talks to Dr Padman Vamadevan about a new partnership that the NHS has struck with a genomics testing firm to give more cancer patients access to complex genetic testing for their disease. 

Dr. Ashwin Singh Parihar sits down with Dr. Louise Emmett to discuss how post-therapy Lutetium-177 PSMA SPECT/CT may help predict overall survival in patients with metastatic castration resistant prostate cancer and shape future treatment decisions. Drawing from the ENZA-p trial run by ANZUP cancer trials group, they explore quantitative imaging, treatment response assessment, adaptive dosing strategies, and the growing role of theranostics in precision oncology.   177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Ayati et al. Radiology 2026; 319(1):e252672.

As cancer incidences continue to rise across the country. The Presidents of Ireland's cancer care representative bodies, along with the Irish Cancer Society, are warning that key parts of the care system are struggling to keep pace. Speaking to Anton was Dr Michael McCarthy the President of the Irish Society for Medical Oncology and is a signatory on the joint letter.

As cancer incidences continue to rise across the country. The Presidents of Ireland's cancer care representative bodies, along with the Irish Cancer Society, are warning that key parts of the care system are struggling to keep pace. Speaking to Anton was Dr Michael McCarthy the President of the Irish Society for Medical Oncology and is a signatory on the joint letter.

Send us Fan MailWelcome to Episode 30 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.What does it really take to make cancer care smarter? In this episode of Experts on Point, host Rachael Babin is joined by Associate Professor Jenny Liu and patient advocate Beth Ivimey to explore how precision oncology is reshaping not only cancer treatment but the way clinical trials are designed and delivered. It's a conversation that we hope you will find inspiring - its about combining innovation with compassion—and  its a reminder that some of the biggest advances in oncology may come not only from scientific breakthroughs, but from building systems that put patients at the centre of every decision. Drawing on both clinical expertise and lived experience, they discuss genomic testing, trial navigation, toxicity management, patient partnership and the challenges of ensuring the right patient reaches the right trial at the right time. Together, they reflect on why the future of cancer research depends as much on smarter systems and meaningful collaboration as it does on scientific innovation.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

The Multinational Association of Supportive Care in Cancer (MASCC) and IC-OS jointly published a paper titled: “Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement”. This is a critical contribution to the literature because it was produced by and for the hematology/oncology community. Historically, cardio-oncology has been dominated by cardiologists. We are seeking to address this by working closely with the hematology/oncology community on various projects including publications. Leading contributors discuss this important contribution on this episode. You can read the full statement here: https://link.springer.com/article/10.1186/s40959-026-00481-3

Send us Fan MailFor decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto's success in prostate cancer signals for the future of radioligand therapy.

Fifteen years after her cancer diagnosis, Sheila Dillon asks what role food could play in cancer treatment, prevention and recovery - and why it is still so often overlooked.Earlier this year, the Government published a new 10-year National Cancer Plan for England, aiming to save 320,000 lives and ensure three in four people survive at least five years after diagnosis by 2035. It's been welcomed as an ambitious strategy, yet some say it has little to say about diet. References to food focus largely on reducing obesity - by making supermarkets to monitor and report on sales of healthy and unhealthy foods, and expanding access to weight-loss drugs. It also includes commitments to improving hospital food for children with cancer, and introducing prehabilitation programmes via the NHS App by 2028. So where does that leave food itself - in treatment, in recovery, and in the risk of relapse?Featuring interviews with: Clare Doney, the clinical lead for personalised care for the Northern Cancer Alliance covering the North East and North Cumbria. Dr Giota Mitrou, Executive Director of Research and Policy at World Cancer Research Fund International Prof. Robert Thomas, head of oncology at the Royal London Hospital for Integrated Medicine, part of University College Hospital and consultant oncologist at Addenbrooks hospital in Cambridge.Produced by Natalie Donovan for BBC Audio in BristolResources:https://mywellbeingspacenca.nhs.uk/https://www.wcrf.org/living-well/living-with-cancer/cancer-and-nutrition-helpline/These links will take you to an external website. The BBC is not responsible for the content of external sites.

"There are a huge array of medical dynamics that people endure, and when they leave a lasting impact, a word that we don't use widely enough is the word 'trauma.' There's an entire category of phenomena in the medical arena that are, in fact, traumatic. One way we know that these experiences are traumatic is that we know that huge portions of people who experience things like cancer do indeed develop problems like [post-traumatic stress disorder]," James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about understanding medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 26, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge of medical trauma and its effects on patients with cancer, caregivers, and healthcare professionals. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 315: Processing Grief as an Oncology Nurse Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 276: Support Young Families During a Parent's Cancer Journey Episode 257: Redefining the Bell: The Ethics of Hope for Oncology Nurses and Patients Episode 103: What Oncology Nurses Need to Know to Support Caregivers ONS Voice articles: 'Between Two Kingdoms' Gives Us a Glimpse Into How Patients and Families Experience Malignancy AYA Cancer Survivors Experience Five Times Higher Depression Rates Than Individuals Diagnosed at Older Ages From Stigma to Support: Changing the Cancer Conversation Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress When the Story Ends, Cancer Does Not Win: Reframing Death in Terminal Cancer Care Word Choice Matters When Caring for Patients With Cancer ONS course: ONS Psychosocial Dimensions of Cancer Care™  Clinical Journal of Oncology Nursing articles: Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Trauma-Informed Care Addressing the Mental and Emotional Needs of Patients With Cancer Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Many people have a notion about what medical trauma is, but perhaps they lack a definition. I use a definition that is deliberately broad because I think it is better to be inclusive than exclusive. A medical trauma to me is a medical experience or a medical encounter that basically leaves a mark. It leaves an emotional mark, and that mark is significant enough to disrupt your daily life." TS 2:06 "When somebody develops a life-threatening illness—let's say cancer—it's not their problem only. It's very much a family problem. It affects any manner of people. There is literature that says that family members of people with life-threatening conditions often have rates of PTSD that are every bit as high as the patients do. There's also literature that says that if we can identify this issue as a family problem—a family challenge, not just an individual challenge—then very often that patient is going to do better." TS 8:23 "We just need to make space for people to feel however they feel. And we need to emphasize, I think, that in some ways, even though there's no cancer on the scan, cancer casts a long shadow in the lives of people, which is why when patients after cancer see their primary care provider, when they come back for a checkup with oncology, we need to continue this conversation of 'How is your mental health? Are you okay? How's your anxiety? How are you managing?' … We need to be really curious and kind, and we need to query people about how they're doing, even if officially they don't have cancer." TS 16:20 "Trauma-informed care has become a bit of a buzzword in our culture. But when it is engaged correctly, I think it's really important. And I think in a nutshell, what it means is that as providers, we need to recognize that some situations and circumstances are likely to be traumatic, and we need to pivot and engage people differently now that we know that. Specific features of trauma-informed care might be we're really going to value your emotional safety. We're going to emphasize that. We are going to emphasize boundaries. We are going to ask your permission instead of telling you how to do things. We are going to be really attentive to the language we use to engage you because we're aware of there might be things about your situation that are really triggering." TS 28:15 "I think one [misconception] certainly is that it is only afflicting and affecting people who are frail or weak—not very strong. That's emphatically not true. But that's a popular misconception—that if I'm strong enough, if I'm resilient enough, this experience will not be traumatic to me. It's just not true. Medical trauma doesn't just happen in emotionally weak people. Medical trauma can impact people of all sorts." TS 33:42 "The other misconception, I think, is that there is no hope for people in the throes of medical trauma. I'm not advocating 'hopium,' It's a term that was coined, I think, during the pandemic. I don't think that living with medical trauma is all rainbows and unicorns and shiny things. But the truth is, if you get the treatment that you need, you can find a way to thrive with medical trauma even as you're impacted by medical trauma. This, this 'both-and-ness' is really true. You can both be adversely affected and you can even find some beauty in your struggle. Both can be true." TS 34:13 "I wish people understood that there is a name for this phenomenon. We're naming it here today medical trauma. Not everyone who has cancer has medical trauma—not even close—but there are many people who do. And I think many of those people, they don't quite have a name for it. And when I introduce this name for it—trauma—many of them say, 'Oh, my gosh, that makes so much sense. I didn't quite understand why I was struggling so much with this. I didn't quite understand why it casts such a long shadow in my life. I didn't really understand why I was having panic attacks every time I had to get another scan at the oncology office to see if my breast cancer had returned. Now I understand. Now I understand it's because it was trauma.'" TS 35:09

Dr Chérine Bazzane spent years training as a family physician and teaching medicine. Then cancer entered her own family, and the system she understood professionally became something far harder to navigate as a daughter.In this episode of The Wellness Algorithm, Anshu Bahanda speaks with Dr Chérine about integrated cancer care and the gap many patients and families experience between medical treatment and everyday coping. They explore why a diagnosis can unsettle even those who know the language of medicine, and how stress, exhaustion and uncertainty can shape the way people move through treatment.The conversation also looks at the role of sleep, nutrition, emotional resilience and nervous system awareness in supporting patients alongside conventional care.Leave a review

What does it actually look like when a doctor refuses to give up on a patient, even when the statistics say there's nothing left to do?In this episode of Integrative Cancer Solutions, Dr. K sits down with Dr. William Nelson, NMD, a naturopathic oncologist with nearly 30 years in practice, to walk through the tools and thinking behind some of his most remarkable patient outcomes. From a stage 4 colon cancer case with an inoperable tumor and mets to the liver and lung who now has no evidence of disease, to the science behind mistletoe fever induction and regional hyperthermia, this conversation goes deep into what integrative cancer care can do when it's done right. Dr. Nelson also breaks down the real difference between naturopathic medicine and functional medicine, why chemotherapy alone can never finish the job, and how he uses mistletoe not as a replacement for conventional care but as the immune reset that makes everything else work better.If you or someone you love is navigating a cancer diagnosis and wondering whether there's more to the picture than surgery, chemo, and radiation, this episode is worth your full attention.Key Takeaways:0:00 Introduction1:12 Naturopathic oncology treats the whole patient not just the tumor6:06 Naturopathic medicine vs functional medicine10:07 Why more supplements is not better in cancer care13:00 Patients hiding integrative care from their oncologist15:46 Stage 4 colon cancer with no evidence of disease19:04 Mistletoe fever induction for advanced cancer25:07 Hyperthermia delivers 1500% more chemo without more toxicity29:44 Mistletoe as immune modulator not just cancer killer33:11 How mistletoe teaches the immune system to recognize cancer36:22 Mistletoe used safely alongside immunotherapy38:48 Believe Big offers financial support for mistletoe treatment Schedule a Free 15-Min Cancer/Lyme Consultation at The Karlfeldt Center: 208-338-8902Resources:Believe Big — https://www.believebig.orgJohns Hopkins Medicine — https://www.hopkinsmedicine.org Medical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions.

This episode explores why carbon ion therapy is becoming one of the most closely watched developments in radiation oncology. The conversation should connect patient need, the engineering scale behind heavy particle therapy, and the larger research questions now shaping how carbon ions may fit alongside photon and proton therapy in the future. How to listen and stay connected: Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode. Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: https://mayocl.in/3EcNPNc Connect with Mayo Clinic: Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/ Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic

 In this episode of Onc Now, Stephen Chan, Clinical Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong, explores the evolving landscape of hepatobiliary and pancreatic cancers. From advances in translational science and precision therapies to the challenges of neuroendocrine tumour care, Chan reflects on the progress made in oncology and the breakthroughs still needed. He also discusses his work with the Hand-in-Hand Cancer Foundation, highlighting the importance of education, compassion, and holistic support for patients and their families.  Timestamps:    00:00 – Introduction    01:18 - Current Hepatobiliary and Pancreatic Landscape   03:23 - Translational Science and Patient Outcomes   05:06 - Founding the Hand-in-Hand Cancer Foundation   06:53 - Advances in Precision Cancer Therapies   08:54 – Rising Incidence of Pancreatic Cancer Post COVID-19  10:45 - President of the International Liver Cancer Association  12:46 - Challenges in Neuroendocrine Tumour Care   14:32 - Future Breakthroughs in Cancer Care   16:02 - Three Wishes for Oncology's Future 

Breakthroughs in cancer care often begin long before a therapy reaches patients. Foundational research into disease biology, cellular mechanisms and immune system function continues to drive innovations that are transforming how cancer is understood and treated. In this episode of Healthcare Insider, Shannon Mortland sits down with Dr. Siddharth Balachandran, PhD, of Temple Health's Fox Chase Cancer Center, to discuss the scientific discoveries helping fuel the future of cancer immunotherapy. The conversation explores how research into influenza viruses and cell death pathways contributed to advances in immunology, why foundational science remains critical to clinical innovation, and how today's laboratory discoveries are informing tomorrow's cancer treatments. What You'll Learn How foundational research helps drive breakthroughs in cancer care The connection between influenza research and advances in immunology Why basic science remains essential to developing new therapies How immune system discoveries are influencing cancer immunotherapy The role of translational research in bringing innovations from the lab to patients What emerging research may mean for the future of cancer treatment and clinical trials

Guest: Urs Weber, MD For patients with ALK-positive non-small cell lung cancer, staying on therapy often means staying ahead of treatment-related toxicities. Join Dr. Urs Weber, Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus, as he explores practical strategies for toxicity management, dose optimization, and shared decision-making to help support durable outcomes.

Truth Be Told with Booker Scott – Cancer care needs truth, transparency, and real patient choice. Families question a system that often rushes toward chemo, radiation, and surgery while overlooking nutrition, prevention, and natural approaches. Operation World Without Cancer highlights the demand for honest debate, integrative care, and freedom to pursue every path toward health and healing...

Music is more than entertainment — it's a form of healing. In this episode of the miniVHAN podcast, PJ Cowan, senior program manager of the nonprofit Musicians On Call, shares how they are transforming patient care through live music, emotional connection and whole-person care.

June 22, 2026 ~ Bethany Parish discusses the latest in oncology care and how Corewell Health is pushing forward in cancer treatment and patient support. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Eden Biltibo is a Hematology/Oncology clinical fellow at Vanderbilt University Medical Center in Nashville, TN.Dr. Camille V. Edwards is a board-certified primary care physician at Boston Medical Center (BMC) and an Assistant Professor of Medicine at Boston University Chobanian & Avedisian School of Medicine.Dr. Joselle Cook is a hematologist/oncologist at the Mayo Clinic in Rochester, Minnesota, where she specializes in dysproteinemia, plasma cell disorders, and precursor conditions.THIS PODCAST IS BROUGHT TO YOU IN PARTNERSHIP WITH THE MULTIPLE MYELOMA RESEARCH FOUNDATION.

In this inspiring episode, Dani is joined by two breast care clinical nurse specialists from Milton Keynes University Hospital NHS Foundation Trust to explore what's possible when healthcare professionals truly listen, learn and work together to improve menopause care for women after cancer treatment.If you're a patient, this is a must-listen so that you can set realistic expectations of what's possible. If you're a healthcare professional, you'll be blown away by what Jaqcui and her team have achieved through hard work and persistence.Clinical Nurse Specialist Jacqui shares how she helped shape and evolve the support offered within her team around menopause after cancer, bringing colleagues together, opening up important conversations, and helping create more compassionate, informed care for patients navigating life after treatment. She is joined by her colleague, Christina for an honest discussion about what they've learned from patients over the years, the gaps they began to recognise, and the practical changes that can happen even within stretched NHS services and limited resources.Dani says, “Thank you for being utterly amazing!”Jaqcui and Christina mention Dani's book and say how helpful it is for them. You can buy a copy here: https://amzn.eu/d/04P0N9FXAnd here is www.menopauseandcancer.org for more information and support.Episode Highlights:00:00 Intro08:06 Addressing menopause post-cancer treatment14:24 Learning from patient engagement17:06 New prescribing practices in oncology20:25 Discussing Tamoxifen Prescription Options26:16 Discussing hormone therapy side effects27:46 Discussing bone health in menopause36:37 Challenges in patient care response37:53 Menopause care post-cancer42:44 Focusing on menopause and cancer43:52 Planning patient support events49:11 Empowering patient-doctor conversationsConnect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub

What if some of the most promising discoveries in cancer research were hidden from public view?  Discover how plant-based compounds may help support healthy cells and why addressing root causes matters in cancer prevention and recovery.  Join me and my guest, Sylvie Beljanski, President of The Beljanski Foundation, to learn more about her father's pioneering work in molecular biology, his discovery of plant extracts that selectively target cancer cells, and the remarkable story behind a research legacy that continues today.

Today's guest is Ann Wax, RN, an oncology nurse with more than 50 years of experience caring for people affected by cancer. Today, Ann serves as an Oncology Doula™, speaker, educator, author, and patient advocate, helping patients and families navigate the emotional and human side of the cancer journey.Throughout her career, Ann discovered that some of the most meaningful aspects of care happen outside of treatments, procedures, and test results. She calls this "The Care Between the Care™"—the compassion, dignity, support, and connection that patients and families need during diagnosis, treatment, survivorship, and beyond.In this conversation, Ann shares insights gained from decades at the bedside, discusses the role of an Oncology Doula™, and explains why dignity should never be viewed as an extra—it should be an essential part of every patient's care.Whether you are a patient, survivor, caregiver, healthcare professional, or someone supporting a loved one through cancer, this episode offers powerful reminders about the impact of kindness, presence, and truly seeing the person behind the diagnosis.Resources:Ann's email: annwax7@gmail.comAnn's LinkedIn: https://www.linkedin.com/in/annwax/Ann's Book on Amazon: Op-Ed on CancerFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

#thismorning | From #Vaccines to Targeted #Therapy: The Future of #Cancer #Care | Christina Annunziata, MD, PhD, American Cancer Society | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #wellness

Cancer is never convenient, and it never arrives when a patient is truly prepared, according to Daniel C. McFarland, DO, who began the most recent episode of Oncology On the Go with this sentiment. When individuals enter the high-stakes, highly coordinated world of oncology, they do so under extreme duress, often presenting the versions of themselves that are most under stress. In this environment, clinical teams frequently encounter behaviors that get unfairly lumped into the vague and pejorative category of the “difficult patient.” What happens when these challenges stem from an underlying personality disorder rather than just temporary situational anxiety? In this episode, McFarland was joined by psycho-oncology expert Kaleena Chilcote, MD, to unpack the inner workings of personality styles and disorders within oncologic science. Together, they explored the Diagnostic and Statistical Manual of Mental Health Disorders (DSM) diagnostic framework, spanning the eccentric, dramatic, and anxious categories. They discussed how these enduring, pervasive traits impact a patient's health care journey. Shifting the conversation away from the stigma of labels, McFarland and Chilcote delivered actionable, real-world advice for oncology teams. They discussed how to utilize objective, descriptive charting; initiate a pause to check your own provider emotions; and build highly consistent, structured boundaries. From managing frequent phone calls to intentionally scheduling short, high-frequency touchpoints, the pair provided a roadmap for turning interpersonal conflict into therapeutic collaboration, proving that underneath the defense mechanisms, every patient has a uniquely valuable strength to connect with. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being a psycho-oncology editorial advisory board member for the journal ONCOLOGY®. Chilcote is director of Psycho-Oncology in the Department of Palliative and Supportive Care at the Taussig Cancer Center, part of the Cleveland Clinic. 

Brian Kukan is a treasure. Not only is he doing powerful work to help those with cancer using his reiki, he is a musician and mathematician. I am glad to have him back on the show to demonstrate his skill in numerology.He reads the numerology for the AI model titans and we are left speechless.If cancer has ever impacted you and yours, please donate to the group below.And Brian Kukan does remote reiki sessions, selling gift certificates as well. Find him and all his links below.Brian Kukan's LinksLA Reiki Guy, Brian Kukan's websiteweSPARK orgDonate a reiki session to a cancer patient!Send us Fan MailSupport the showSupport Curious Cat, an independent, human-made podcast!Anxious about AI? Take two minutes to contact your local politician and ask them to tap the brakes on this technology. Still worried? Contact one of the orgs below and get involved. But for today, hug your kid, cook food and really breathe in deep as it simmers, walk in nature, brush a cat, donate to the food bank, brew a cup of tea, or draw a five-minute portrait of your dog. ***Is AI the Devil? on Substack!***Hero Organizations:80,000 HoursCenter for Humane TechnologiesState of Surveillance, an organization that helps foster online privacyBuy Curious Cat Podcast a Coffee!

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with W. Kimryn Rathmell, MD, PhD, about the new and evolving ways cancer care is delivered, building networks through advocacy and more. ·       Who is Dr. W. Kimryn Rathmell?  2:17 ·       Jain and Rathmell discuss the need for physician scientists in administrative leadership. 11:37 ·       How do you think networks and communities can impact careers? 17:08 ·       What are your thoughts on using social media in the cancer space? 22:35 ·       How do you think AI is going to transform the way we deliver care? 26:21 ·       As you have navigated your career, how have you approached challenges around being a woman in leadership roles? 29:29 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Rathmell can be reached on LinkedIn. Jain reports no relevant financial disclosures. Rathmell reports a relationship with Interact Therapeutics, as well as institution relationships with Merck and Sitryx.

Send us Fan MailA cancer diagnosis can change everything in an instant. One conversation. Three words: "You have cancer." Suddenly, patients and families are faced with uncertainty, fear, and countless questions about what comes next.In this episode of MedStar Health DocTalk, host Debra Schindler sits down with medical oncologist and hematologist Dr. Ankit Madan of MedStar Southern Maryland Hospital Center, to discuss the critical first steps after a cancer diagnosis. Dr. Madan explains how patients move from diagnosis to treatment, how cancer is staged, and why building a multidisciplinary care team is essential for the best possible outcomes.The conversation explores the emotional impact of hearing a cancer diagnosis, the importance of patient navigators, social workers, nutritionists, mental health professionals, and the role patients play as active partners in their own care. Dr. Madan also discusses treatment advances, clinical trials, immunotherapy breakthroughs, second opinions, and practical advice for patients and families navigating one of life's most challenging journeys.Whether you or a loved one has recently been diagnosed with cancer, this episode offers guidance, reassurance, and expert insight into what happens after the diagnosis—and how patients can move forward with confidence and support.Topics covered:• Coping with the emotional impact of a cancer diagnosis• Understanding cancer staging and treatment planning• The role of biopsies, CT scans, PET scans, and additional testing• Building a multidisciplinary cancer care team• Patient navigators, social workers, and support services• Shared decision-making and patient autonomy• When to seek a second opinion• Clinical trials and emerging cancer treatments• Immunotherapy and advances in cancer care• Nutrition, exercise, and mental health during treatment• Cancer survivorship and ongoing surveillanceTo learn more about cancer care at MedStar Health, visit MedStarHealth.org/Cancer.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

In this episode of Habari Live, Damon Ellison and Iesha Rowan examine the heartbreaking case of retired San Francisco firefighter Ken Jones, who died after his insurance provider denied coverage for a cancer treatment prescribed by his oncologist. Jones spent 17 years serving his community before being diagnosed with Stage 4 lung cancer, raising difficult questions about healthcare access, insurance companies, and whether life-saving treatment decisions should be determined by doctors or corporate policies.The conversation expands into the broader healthcare debate, including insurance denials, Medicare regulations, first responder cancer risks, and growing calls for healthcare reform in America.We also break down the biggest political clips and stories of the week:

A Place Called Hope: Dr. Francisco Contreras on Cancer Care, Faith, and Integrative Healing Episode Description In this episode of Conversations with a Chiropractor, Dr. Stephanie Wautier sits down with Dr. Francisco Contreras of Oasis of Hope in Tijuana, Mexico, for a thoughtful and deeply meaningful conversation about cancer care, hope, faith, prevention, and whole-person healing. Dr. Contreras shares the story of Oasis of Hope, founded by his father, Dr. Ernesto Contreras, more than 60 years ago. What began as a vision to care for the physical, emotional, and spiritual needs of cancer patients has grown into an international integrative oncology center serving patients from around the world. Stephanie and Dr. Contreras talk about the importance of treating the whole person, not just the diagnosis. Their conversation moves through integrative cancer care, immune support, natural and conventional treatment options, nutrition, exercise, stress, spiritual strength, early detection, breast cancer screening, biopsy concerns, and the role of hope in the healing process. Dr. Contreras also discusses why he believes patients need clear, understandable information when facing cancer. With so much information online, the process can feel overwhelming and frightening. His message is steady and compassionate: cancer is serious, but it does not have to immediately steal a person's joy, clarity, or hope. This episode includes discussion of cancer treatment, prevention, screening, integrative oncology, COVID vaccination concerns, and medical decision-making. It is meant to inform, encourage, and spark deeper questions, not replace personal medical advice. Anyone dealing with cancer, screening decisions, treatment options, supplements, or major health changes should work directly with a qualified medical team that understands their individual situation. In This Episode, Discover The story behind Oasis of Hope and its 60-year history How Dr. Ernesto Contreras helped shape a whole-person approach to cancer care Why Dr. Francisco Contreras believes emotional and spiritual support matter in healing What integrative oncology means at Oasis of Hope Why some natural therapies are studied but not widely approved or adopted How immunotherapy and immune support fit into the Oasis of Hope approach Dr. Contreras' perspective on rising cancer rates in younger people Simple lifestyle steps that may help reduce cancer risk The importance of fruits, vegetables, movement, stress reduction, and spiritual strength Why cancer symptoms often appear after disease is already present Mammograms, ultrasound, MRI, thermography, and early detection How Dr. Contreras thinks about biopsy risk versus diagnostic benefit When someone might consider contacting Oasis of Hope Why clear information matters when patients are overwhelmed The role of hope, mindset, faith, and joy during a cancer journey Stay Connected & Explore Learn More About Dr. Francisco Contreras and Oasis of Hope: Oasis of Hope: https://www.oasisofhope.com/ Dr. Francisco Contreras: https://www.oasisofhope.com/doctor/dr-francisco-contreras/ Request a Free Consultation: https://www.oasisofhope.com/contact-us/ Download Dr. Contreras' Free Cancer E-Book, The Art & Science of Undermining Cancer: https://www.oasisofhope.com/ Episode Sponsor: Learn more about Lemongrove Oil: https://www.lemongroveoil.com/ Connect with Conversations with a Chiropractor: Follow Us on YouTube: http://www.youtube.com/@ConversationswithaChiro Follow Dr. Stephanie on Facebook: https://www.facebook.com/wautierwellness Email for show-related inquiries and sponsorships: drstephaniewautier@yahoo.com Want to be a guest on Conversations with a Chiropractor? Send Stephanie Wautier a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/drstephanie Credits Podcast production by Brand|Sound. Start your podcast journey by emailing brandsoundpodcasts@gmail.com. Chapters 00:00 Introduction to Conversations with a Chiropractor 04:03 Meet Dr. Francisco Contreras 04:21 The Story Behind Oasis of Hope 08:08 Cancer Care Statistics and a Different Approach 08:46 Integrative Oncology and Treatment Options 10:47 Natural Therapies, Research, and FDA Approval 11:38 Immunotherapy and the Immune System 12:45 Science, Natural Therapies, and Patient Care 15:20 Rising Cancer Rates in Younger People 17:56 COVID Vaccination Questions and Cancer Concerns 21:20 Early Warning Signs and Cancer Prevention 22:23 Fruits, Vegetables, Exercise, and Risk Reduction 24:27 Stress, Immunity, and Spiritual Strength 26:05 Keeping Wellness Simple and Sustainable 29:36 Breast Cancer Screening, Mammograms, and Thermography 33:07 Biopsy Concerns, Risk, and Diagnostic Benefit 36:19 When to Contact Oasis of Hope 38:47 Referrals, Free Consultations, and Becoming a Patient 39:32 Dr. Contreras' Books and Free Cancer E-Book 42:10 Cancer Is Not Necessarily a Death Sentence 43:37 Hope, Mindset, and the Power of Joy 45:22 Final Thoughts and Closing

Cancer is increasingly recognized as a major global health challenge, yet for people living through war, displacement, and humanitarian crises, access to even basic oncology services can be difficult or impossible. While emergency responses typically focus on trauma care, infectious diseases, and immediate survival needs, cancer care remains largely absent from many humanitarian health programs. A review paper on this topic was published in Volume 17 of Oncotarget titled “Cancer without borders: Policy frameworks for oncology care in humanitarian and conflict settings.” The study was led by first and corresponding author Pragnesh Parmar, with Gunvanti Rathod as co-author, both from AIIMS Bibinagar, Telangana, India. Full blog - https://www.oncotarget.org/2026/06/03/cancer-care-often-overlooked-in-humanitarian-crises/ Paper DOI - https://doi.org/10.18632/oncotarget.28856 Correspondence to - Pragnesh Parmar - drprag@gmail.com; (ORCID: orcid.org/0000-0002-8402-8435) Abstract video - https://www.youtube.com/watch?v=zXlhIBZyJ6Q Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28856 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cancer care, humanitarian crisis, tele-oncology, global health policy, oncology triage To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

“I mean, I believe so strongly that food, what we eat, matters.” —Jen NolanIn this episode of the Real Health Podcast, Dr. Michelle Niesley is joind by Jen Nolan, owner of Remission Nutrition and nutrition advisor at Riordan Clinic, to explore nutrition recomendations and the differences between what is recommended during active treatment and after treatment.

In this episode, Leigh Ann welcomes Diana Salcido to share her deeply personal story of being diagnosed with stage 3C colon cancer after nearly a year of symptoms, medical dismissal, panic, abdominal pain, and an inner knowing that something was wrong. Diana walks listeners through the frightening path to diagnosis, including ER visits, being told she was simply anxious or constipated, an eventual bowel obstruction, emergency surgery, and the discovery that the cancer had spread to four lymph nodes. She also shares the complications that followed, including a leak, a second emergency surgery, an ileostomy, severe weight loss, pleural effusion, abscesses, additional surgery, and the loneliness of healing from injuries and trauma that others could not always see. Diana and Leigh Ann discuss the emotional toll of cancer, the difficulty of making treatment decisions amid conflicting medical opinions, and Diana's choice to pursue an integrative path guided by body intuition, discernment, and personalized support. The conversation explores the physical, emotional, and spiritual layers of healing, including trauma work, faith, rest, sunlight, diet changes, supplements, acupuncture, frequency therapies, and learning when to pivot based on what the body is communicating.Product Discount Codes + LinksHoolest: Website (Discount Code: THEACCRESCENT10)Froya Hair Care: Website (Link gives 10% off)Herbal Face Food: Website (Discount Code: LAL30)The Fullest: Website (discount code: LEIGH15)Episode LinksDiana's GoFundMeRelated EpisodesEp. 228: Dr. Lori Bouchard - The Missing Pieces in Cancer Care, Metabolism, Trauma, and Whole-Person HealingEp. 176: Leigh Ann Lindsey - How I Work with Cancer Patients to Address Emotional Root Causes to DiseaseWork w/Leigh AnnLearn: What is EVOX Therapy?Book: Schedule a Session or FREE Discovery CallMembership: What is The Healing Alchemy MembershipConnect w/Me & Learn MoreWebsiteInstagramTiktokYoutube

Message us!In this episode of Whitley Penn Talks, host Emily Landry is joined by Dr. Paul Bowman, longtime pediatric oncologist and co-chair of Leukemia Texas, who shares clear and hopeful insights on what leukemia is and how far treatment for the disease has come. Alongside him, Ashley Oviedo opens up about her daughter, Perry's, diagnosis, offering an honest and emotional look at the fear, uncertainty, and strength that define a family's journey through cancer.Together, they highlight the critical role organizations like Leukemia Texas play in supporting families medically, financially, and emotionally through their most challenging times. From the first signs of illness to the importance of accepting help and holding onto hope, this conversation is a reminder that no one should fight cancer alone.Fill out this form to have new episodes sent right to your inbox! Follow Whitley Penn on LinkedIn, Instagram, Facebook, and X for more industry insights and thought leadership!

The ACCC Global eXchange series is committed to highlighting cross-regional collaborations that advance cancer care delivery and workforce development nationwide. In this episode of CANCER BUZZ, Dr. Michael Cavnar discusses his humanitarian efforts in Zambia and why volunteering in this capacity is crucial and meaningful for US oncology providers. "The more you're around people that are different than you, the more different perspectives you see. It creates a more open mind and a better world, because people understand each other better." – Michael Cavnar, MD   Guest: Michael Cavnar, MD GI Surgical Oncologist UK HealthCare/Markey Cancer Center Lexington, KY Resources: Shared Solutions for Rural Oncology: Insights Across the Americas Breast Cancer Knowledge Gaps and Misconceptions Among Non-Medical Female University Students in Southwestern Nigeria A Global Perspective: Innovative Care and Supporting Women in Medicine in Nigeria #ACCCNOC: Advancing Global Health Equity  

Cancer care is evolving, and today's conversation with Martha Tettenborn dives into one of the most overlooked aspects of healing and prevention: metabolic health. Martha is a cancer survivor, author of Hacking Chemo, and currently works with Dietary Therapies, where she helps support patients using evidence-based nutritional and metabolic approaches alongside conventional cancer care. In this follow-up conversation, we move beyond Martha's personal story and explore what she's seeing firsthand in patients today. We discuss the growing connection between insulin resistance, blood sugar dysregulation, inflammation, and cancer progression — and why metabolic health deserves a much bigger place in the cancer conversation. Martha also shares practical insights into keto therapies, fasting during treatment, common mistakes patients make when trying these approaches on their own, and the importance of individualized care and professional guidance. This episode is not only valuable for those navigating cancer, but also for anyone struggling with fatigue, inflammation, insulin resistance, stubborn weight gain, or chronic metabolic dysfunction. So many of the foundational principles that support metabolic healing apply broadly to overall health and disease prevention. ✨ How Martha's perspective has evolved from cancer survivor to working directly with patients at Dietary Therapies ✨ Common metabolic patterns she is seeing in cancer patients today ✨ The connection between insulin resistance, blood sugar dysregulation, and cancer progression ✨ What people are misunderstanding about keto and fasting for cancer care ✨ Who may not be a good candidate for fasting during treatment ✨ The biggest mistakes people make when trying dietary therapies on their own ✨ How metabolic therapies can work alongside conventional oncology care ✨ Why nutrition and metabolic health are still often overlooked in cancer treatment ✨ Lifestyle habits and strategies that may support long-term healing and recurrence prevention ✨ Why metabolic health matters even for those who have never faced a cancer diagnosis LINKS & RESOURCES: Learn more about Martha's work through Dietary Therapies Get Martha's book Hacking Chemo READY TO IMPROVE YOUR METABOLIC HEALTH? ✨ My 90-Day COMPASS Reset begins Monday, June 1st! This guided reset is designed to help you stabilize blood sugar, improve energy, reduce inflammation, and begin healing your metabolism with sustainable strategies focused on meal timing, metabolic flexibility, circadian health, and nervous system support. The only requirement to join is being on the Feel Great System. Get started here: https://ufeelgreat.com/c/SHANAH

In recognition of National Women's Health Month, this episode of Thinking Thoracic analyzes the evolving landscape of female-specific lung cancer care. Co-hosts Dr. Erin Gillaspie and Dr. Jane Yanagawa sit down with guest Dr. Leah Backhus to discuss a critical disparity: lung cancer is the leading cause of cancer death among women, yet screening practices remain inequitable.    This timely episode moves beyond smoking history to examine the rise of lung cancer in never-smokers and Asian women. From the "stigma" of a diagnosis to innovative solutions like co-scheduling screenings with mammograms, providing a powerful call to action for more inclusive, biomarker-driven care. 

Host: Mindy McCulley, MS, Extension Specialist for Instructional Support, Family and Consumer Sciences Extension, University of Kentucky  Guest: Dr Ayman Qasrawi, Assistant Professor of Medicine, (Hematology) and Dr. Ruta Arays, Assistant Professor of Medicine (Medical Oncology), Markey Cancer Center Cancer Conversations Episode 75 Host Mindy McCulley interviews Dr. Ayman Qasrawi (Dr. Q) and Dr. Rita Arays of the UK Markey Cancer Center about multiple‑modality management and interdisciplinary collaboration in treating advanced melanoma. The episode explains tumor‑infiltrating lymphocyte (TIL) and why this personalized immunotherapy can produce durable responses when other options fail. Key takeaways include the multidisciplinary workflow needed to deliver TILs in Kentucky, candidate selection and timing/referral considerations, program availability at UK (and UofL), and implications for future vaccine research and community care.   Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On Twitter @UKMarkey

Christine Fader joins Anita and Mel from Canada to talk about the death of her husband, Michael, and the reality of living through not one but two cancer diagnoses. In 2018, Michael was diagnosed with the “good” kind of throat cancer. In 2020, he was diagnosed with a completely new and far more aggressive lung cancer. By November 2022, he was gone.Michael's terminal cancer was both aggressive and underfunded despite lung cancer being one of the most commonly diagnosed cancers there is. He held onto hope for new treatments as long as he could.The episode also digs into the trauma that can exist underneath cancer care. Christine shares how Michael's childhood trauma and later medical trauma shaped his experience as a patient, and why she is now advocating for trauma-informed cancer care and better education for doctors. With a background in speaking, teaching, and advocacy, she's working to push conversations about cancer beyond survival rates and treatment plans to include the emotional and psychological realities patients and caregivers live through.Find Christine at https://www.christinefader.comSponsored by:BetterHelp.com. Save 10% off the first month of online therapy done securely, online with our unique link: https://trybetterhelp.com/wwdnMint Mobile: Mobile phone plans with great service and coverage starting at $15/month https://trymintmobile.com/wwdnJoin our Patreon for ad-free episodes and more!http://www.patreon.com/wwdnNeed some Snarky Grief merch?http://shop.widowwedonow.comWanna buy us tacos?http://www.buymeacoffee.com/widowwedonowFollow our YouTube channelhttps://www.youtube.com/@widowwedonow Support the show